Loading
SC
SCL사이언스 Stock: price and insider trades · South Korea
1 insider bought €12k of shares over the last 90 days, the latest filed 06 Aug 2026.
SCL사이언스: what insiders have been doing
This page follows insider dealings at SCL사이언스 as filed with DART (FSS), a company from the Health Care sector. Between 18 October 2025 and 18 October 2026, 3 insiders published 9 filings.
No insider sold shares on the market over the period. Instead, the filings list 5 purchases, made by 2 insiders. No amount is published for 5 filings, which the totals therefore leave out. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Among those who bought: 1 senior executive.
Compared with its exchange (2,648 companies, median 7 filings), a count of 9 filings is above the norm. The full history, which starts in 2021, counts 35 purchases against 1 sale.
The last purchase on record was published on 6 August 2026, which is 73 days ago. Between a trade and the moment it shows up on DART (FSS), the median delay is 3 days. This delay matters because a trade only becomes useful information once it is public.
In the same sector, recent insider purchases at Anixa Biosciences Inc and Vivos Inc also feature in our signals. This summary is built from DART (FSS) disclosures alone and does not predict where the share price will go.
Insider Decl.
57
Thresholds
n/a
Buy Volume
€32M
35 ops. · all time
Sell Volume
n/a
1 ops. · all time
Who traded when
BuySale김경수3 buys
양춘식3 buys
대신신기술투자조합제15호1 buy
Since the insiders bought
- +36.9%Entry ₩1,680 · Close at T+90 ₩2,300
- +6.4%Entry ₩1,915 · Close at T+90 ₩2,038
- -8.8%Entry ₩2,368 · Close at T+365 ₩2,160
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Fundamental score
Ranked 22,521 of 24,161 companies
18.4
score / 100
Value20
Quality16
FCF yld-6.3%
Earn yld-5.4%
EV/EBITDA·
ROE-15%
Gross mgn19%
Net mgn-18%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
₩2,155
Analyst consensus
Income statement
Revenue₩22B
Gross profit₩4.2B19% margin
EBITDA₩393.3M2% margin
Net income-₩3.9B-11.1% margin
Valuation
Beta0.53
Balance sheet & cash
Market cap₩73.3B
Total debt₩28.8B
Free Cash Flow-₩4.6B
Debt / Equity110%
Profitability & ownership
ROE-14.5%
ROA-0.8%
% insiders54.3%
% institutions0.0%
Last declaration on 6 August 2026
Declarations59 total
Other
Other
603,718 sharesKRXDART:20250110000521
Canonical exit: 3 Apr 2025 (T+90)
603,718 sharesKRXDART:20231124000268
Canonical exit: 16 Feb 2024 (T+90)
603,718 sharesKRXDART:20231113000591
Canonical exit: 6 Feb 2024 (T+90)
603,718 sharesKRXDART:20230823000416
Canonical exit: 31 Oct 2023 (T+90)
603,718 sharesKRXDART:20230814000597
Canonical exit: 5 Nov 2023 (T+90)
25 of 59 declarations
About SCL사이언스
SCL사이언스 is a company operating in the healthcare and pharmaceutical sector, listed on the XKRX market. It specializes in developing innovative solutions for the medical field.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
